Ellence Research Fund Names 11 Grant Recipients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 3
Volume 10
Issue 3

PEAPACK, NJ- Pharmacia Oncology has announced the 11 recipients of its first $1 million Ellence Research Fund, aimed at promoting research to advance the use of anthracyclines in various cancer settings. The recipients were chosen by a scientific advisory board composed of leading oncologists. The company has created a second $1 million Ellence Research Fund and is currently accepting research proposals.

PEAPACK, NJ— Pharmacia Oncology has announced the 11 recipients of its first $1 million Ellence Research Fund, aimed at promoting research to advance the use of anthracyclines in various cancer settings. The recipients were chosen by a scientific advisory board composed of leading oncologists. The company has created a second $1 million Ellence Research Fund and is currently accepting research proposals. (For more information, contact Lynn Stoltzfus at lynn.stoltzfus@am.pnu.com.)

The 2001 winners are: Glenn Bubley, MD, Beth Israel Deaconess Medical Center, Boston; Joan Bull, MD, University of Texas-Houston Medical School; Luke Dreisbach, MD, Arizona Cancer Center, Tucson; Phil Gold, MD, Swedish Medical Center Tumor Institute, Seattle; Daniel Haller, MD, University of Pennsylvania Cancer Center, Philadelphia; and Jon Herrington, PhD, Scott and White Memorial Hospital, Temple, Texas.

Also, Peter Kennedy, MD, Kenmar Research Institute, Los Angeles; Pam Khosla, MD, Rush-Presbyterian-St. Luke’s Medical Center, Chicago; Silvana Martino, DO, John Wayne Cancer Institute, Santa Monica, California; Lajos Pusztai, PhD, M.D. Anderson; and Christopher Ryan, MD, University of Chicago.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content